Navigation Links
Revlimid Approved For Treatment Of Myelodysplastic Syndrome (MDS) by FDA

A new drug treatment, Revlimid for treatment of myelodysplastic syndrome (MDS), a rare blood disorder has been approved by the Food and Drug Administration (FDA). The approval was announced by Celgene Corp, manufacturer of the drug.//

The exact cause of MDS is not known. However, increased incidence of MDS has been noticed following radiotherapy or chemotherapy. Transfusion of blood and blood products (platelet) is the usual form of treatment. Anti-biotics may also be given to treat the associated infection.

Symptoms of MDS include fatigue, generalized weakness, susceptibility to infections, bleeding tendency and fever. The incidence of MDS is as high as 7000 to 12000 in the United States with a majority of the cases diagnosed in patients over 60 years.

The new drug has been approved by the FDA, owing to its improved performance in clinical trials. The need for a blood transfusion was eliminated in patients treated with Revlimid. Infact, following 3 months of therapy, a majority of the patients became independent of transfusions. This effect was observed for an average of 44 weeks.

The new drug closely resembles another drug, Thalomid, known to cause severe birth defects when administered to the pregnant mother. On account of this structural similarity, a ‘black box’ warning would be issued to prevent fetal exposure to Revlimid.

The drug would further be marketed under a strict adherence to a risk-management strategy, called RevAssist. According to the plan, only registered participants of the program (doctors and pharmacists) would be authorized to prescribe or market Revlimid. This is expected to reduce the probability of fetal exposure to the teratogenic drug.


'"/>




Page: 1

Related medicine news :

1. Revlimid Approved By FDA For Multiple Myeloma
2. Levothyroxine Thyroid Hormone Replacement, Approved for Hypothyroidism
3. New FDA Approved Drug To Treat Migraine
4. New FDA Approved Drug NATRECOR For Heart Failure Patients
5. New Oral Rinse For Gingivitis Approved By FDA
6. Child Friendly Zidovudine Preparation for treating HIV infection Approved By The FDA
7. AIDS Generic Drugs Approved by FDA for Sale in US
8. FDA Approved Nerve-Stimulation Therapy Now Available In New York
9. Pfizer’s Eraxis Approved By The FD
10. Inhalers for Kids Was Approved By the FDA
11. Alcoholism Drug Vivitrol Approved By FDA
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/26/2016)... ... June 26, 2016 , ... Pixel Film Studios Released ... , "Film editors can give their videos a whole new perspective by using the ... CEO of Pixel Film Studios. , ProSlice Levels contains over 30 Different presets ...
(Date:6/26/2016)... , ... June 26, 2016 , ... ... once they have been diagnosed with endometriosis. These women need a treatment plan ... require a comprehensive approach that can help for preservation of fertility and ultimately ...
(Date:6/25/2016)... ... ... The temporary closing of Bruton Memorial Library on June 21 due to a possible lice ... overlooked aspect of head lice: the parasite’s ability to live away from a human host, ... a necessary one in the event that lice have simply gotten out of control. , ...
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern Californian, Dr. ... his M.D from the David Geffen School of Medicine at UCLA. He trained in ... to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he ...
(Date:6/25/2016)... ... 2016 , ... Conventional wisdom preaches the benefits of moderation, whether it’s a ... the bar too high can result in disappointment, perhaps even self-loathing. However, those who ... , Research from PsychTests.com reveals that behind the tendency to set ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... 2016 Research and Markets has ... by Type (Organic Chemical (Sugar, Petrochemical, Glycerin), Inorganic Chemical), ... Parenteral) - Global Forecast to 2021" report to ... The global pharmaceutical excipients market is projected to reach ... 6.1% in the forecast period 2016 to 2021. ...
(Date:6/23/2016)... , June 23, 2016 ... CAPR ), a biotechnology company focused on ... today announced that patient enrollment in its ongoing ... Duchenne) has exceeded 50% of its 24-patient target. ... in the third quarter of 2016, and to ...
(Date:6/23/2016)... INDIANAPOLIS , June 23, 2016 ... Tomorrow,s Leaders Scholarship is any indication, the future is ... online at www.diabetesscholars.org by the Diabetes Scholars ... in the way of academic and community service excellence. ... program since 2012, and continues to advocate for people ...
Breaking Medicine Technology: